At present, antiangiogenic drugs such as the VEGF antibody, bevacizumab, in addition to several small molecule VEGF receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib) are an integral part of the armamentarium to combat cancer diseases [3]. Here, VEGFA is linked to cancer.